Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
- Enasidenib (AG-221) NDA Submitted for IDH2m Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - - AG-120 NDA Submission for IDH1m R/R AML Planned by Year End 2017 - - AG-348 Advancing to...
-
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the...
-
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the...
-
- Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback - - Lead PKR Activator AG-348 Advancing into Pivotal Development in Pyruvate Kinase Deficiency - - Company...
-
- Overall Response Rate of 38% and Complete Remission Rate of 18% with Patients on Study up to 24.2 Months - - For Relapsed/Refractory Acute Myeloid Leukemia Patients, Overall Response Rate of 33%...
-
- AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant, Rapid and Sustained Hemoglobin Increases in 15 of 26 Patients with at Least One Missense Mutation and 15 out of 32 Patients Overall -...
-
- Durable Stable Disease Observed for Patients with Non-enhancing Low Grade Glioma and Chondrosarcoma Patients; 42% of Glioma Patients Still on Treatment - - AG-120 Well-tolerated in...
-
- Updated Safety and Efficacy Data from AG-348, AG-519 and Completed Dose Escalation Portion of AG-120 Study to be Highlighted in Oral and Poster Presentations - - Company to Host Investor...
-
– Enasidenib (AG-221) on Track for NDA Submission in IDH2m Positive Relapsed/Refractory AML by Year End – ...
-
CAMBRIDGE, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...